Citi Pharma Limited has announced a major expansion move by planning to acquire 100 percent shareholding of Pakheim International Pharmaceuticals (Private) Limited, a Lahore-based medicine manufacturer. The acquisition is part of the company’s broader strategy to strengthen its position in Pakistan’s growing pharmaceutical sector.

According to a notice submitted to the Pakistan Stock Exchange, the Board of Directors of Citi Pharma approved the proposed transaction on May 6, 2026. The deal includes Pakheim’s assets, operational facilities, licenses, and related business activities, subject to regulatory approvals and completion of due diligence procedures.

Pakheim International Pharmaceuticals is reported to operate an established manufacturing facility and holds a portfolio of DRAP-registered products, which are essential for compliance and distribution within Pakistan’s regulated pharmaceutical market. This makes the acquisition strategically valuable for Citi Pharma’s long-term growth plans.

The move is expected to significantly enhance Citi Pharma’s production capacity while also expanding its product portfolio. By integrating Pakheim’s existing operations, the company aims to improve efficiency, broaden its market reach, and strengthen its competitive position within the local healthcare industry.

Pakistan’s pharmaceutical sector has been experiencing steady growth, driven by rising healthcare demand and increased focus on domestic production. In this environment, consolidation and acquisitions have become a common strategy for companies looking to scale operations and improve supply chain capabilities.

For Citi Pharma, the acquisition represents an opportunity to accelerate expansion without starting new facilities from scratch. Leveraging Pakheim’s infrastructure and regulatory approvals could allow faster market penetration and improved production output.

The transaction remains subject to regulatory clearance and successful completion of due diligence. Once finalized, it is expected to contribute to Citi Pharma’s long-term business diversification and operational strength in the pharmaceutical market.